Lexaria Bioscience signs ~AUD$5.1M clinical study agreement with Novotech for GLP-1-H24-4 trial

Lexaria Bioscience Corp.

Effective Dec 2, 2024: Novotech as CRO for DehydraTECH Cannabidiol + GLP-1 agonists in pre- and Type II Diabetes.
Aggregate costs ~AUD$5.1 million; upfront payments ~AUD$414,600 (direct) and ~AUD$347,800 (pass-through).
Lexaria AU can terminate the Project Agreement with or without cause upon 90 days' notice.
Initial start-up work already completed under a separate Start-Up Agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.